Global Atrial Fibrillation Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Atrial Fibrillation treatment during 2019. Clinical development activities are being undertaken by more than 20 companies including Acesion Pharma, Aetas Pharma, Allergan Plc, Allosteros Therapeutics Inc, AnaBios Corporation and others.
A Significant contribution to the Atrial Fibrillation pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Atrial Fibrillation pipeline included 23 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Atrial Fibrillation condition and increased access to investments is encouraging growth of Atrial Fibrillation drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Atrial Fibrillation drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Atrial Fibrillation therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Atrial Fibrillation pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Atrial Fibrillation. Further, orphan drug status, fast track designation, grants awarded and other special status for Atrial Fibrillation pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Atrial Fibrillation pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Atrial Fibrillation Pipeline candidates-
A Significant contribution to the Atrial Fibrillation pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Atrial Fibrillation pipeline included 23 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Atrial Fibrillation condition and increased access to investments is encouraging growth of Atrial Fibrillation drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Atrial Fibrillation drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Atrial Fibrillation therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Atrial Fibrillation pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Atrial Fibrillation. Further, orphan drug status, fast track designation, grants awarded and other special status for Atrial Fibrillation pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Atrial Fibrillation pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Atrial Fibrillation Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Atrial Fibrillation drugs
- Late phase: Phase 3 and in-approval Atrial Fibrillation drugs
- Company overview
- Snapshot
- Atrial Fibrillation therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Atrial Fibrillation- Disease Overview
2.2 Atrial Fibrillation- Pipeline Snapshot
2.3 Atrial Fibrillation- Pipeline Drugs by Phase
2.4 Atrial Fibrillation- Pipeline Drugs by Company
2.5 Atrial Fibrillation- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Acesion Pharma Atrial Fibrillation Drug Pipeline, H2- 2019
3.2 Aetas Pharma Atrial Fibrillation Drug Pipeline, H2- 2019
3.3 Allergan Plc Atrial Fibrillation Drug Pipeline, H2- 2019
3.4 Allosteros Therapeutics Inc Atrial Fibrillation Drug Pipeline, H2- 2019
3.5 AnaBios Corporation Atrial Fibrillation Drug Pipeline, H2- 2019
3.6 ARCA biopharma Inc Atrial Fibrillation Drug Pipeline, H2- 2019
3.7 Armaron Bio Pty Ltd Atrial Fibrillation Drug Pipeline, H2- 2019
3.8 Boston Pharmaceuticals Inc Atrial Fibrillation Drug Pipeline, H2- 2019
3.9 Correvio Pharma Corp. Atrial Fibrillation Drug Pipeline, H2- 2019
3.10 Dong-A Socio Holdings Co Ltd Atrial Fibrillation Drug Pipeline, H2- 2019
3.11 Espero BioPharma Inc Atrial Fibrillation Drug Pipeline, H2- 2019
3.12 G3 Pharmaceuticals Inc Atrial Fibrillation Drug Pipeline, H2- 2019
3.13 Gilead Sciences Inc Atrial Fibrillation Drug Pipeline, H2- 2019
3.14 HUYA Bioscience International Atrial Fibrillation Drug Pipeline, H2- 2019
3.15 InCarda Therapeutics Inc Atrial Fibrillation Drug Pipeline, H2- 2019
3.16 Merck & Co Inc Atrial Fibrillation Drug Pipeline, H2- 2019
3.17 Milestone Pharmaceuticals Inc Atrial Fibrillation Drug Pipeline, H2- 2019
3.18 Nissan Chemical Industries Ltd Atrial Fibrillation Drug Pipeline, H2- 2019
3.19 OMEICOS Therapeutics GmbH Atrial Fibrillation Drug Pipeline, H2- 2019
3.20 Rhythm Therapeutics Inc Atrial Fibrillation Drug Pipeline, H2- 2019
3.21 The Geneva Biotech Center SA Atrial Fibrillation Drug Pipeline, H2- 2019
3.22 Toa Eiyo Ltd Atrial Fibrillation Drug Pipeline, H2- 2019
3.23 Verseon Corp Atrial Fibrillation Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Atrial Fibrillation- Phase 1 Drug Details
4.2 Atrial Fibrillation- Phase 1 Drug Overview
4.3 Atrial Fibrillation- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Atrial Fibrillation- Phase 2 Drug Details
5.2 Atrial Fibrillation- Phase 2 Drug Overview
5.3 Atrial Fibrillation- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Atrial Fibrillation- Phase 3 Drug Details
6.2 Atrial Fibrillation- Phase 3 Drug Overview
6.3 Atrial Fibrillation- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Atrial Fibrillation- Pre-clinical Phase Drug Details
7.2 Atrial Fibrillation- Pre-clinical Phase Drug Overview
7.3 Atrial Fibrillation- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Atrial Fibrillation- Disease Overview
2.2 Atrial Fibrillation- Pipeline Snapshot
2.3 Atrial Fibrillation- Pipeline Drugs by Phase
2.4 Atrial Fibrillation- Pipeline Drugs by Company
2.5 Atrial Fibrillation- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Acesion Pharma Atrial Fibrillation Drug Pipeline, H2- 2019
3.2 Aetas Pharma Atrial Fibrillation Drug Pipeline, H2- 2019
3.3 Allergan Plc Atrial Fibrillation Drug Pipeline, H2- 2019
3.4 Allosteros Therapeutics Inc Atrial Fibrillation Drug Pipeline, H2- 2019
3.5 AnaBios Corporation Atrial Fibrillation Drug Pipeline, H2- 2019
3.6 ARCA biopharma Inc Atrial Fibrillation Drug Pipeline, H2- 2019
3.7 Armaron Bio Pty Ltd Atrial Fibrillation Drug Pipeline, H2- 2019
3.8 Boston Pharmaceuticals Inc Atrial Fibrillation Drug Pipeline, H2- 2019
3.9 Correvio Pharma Corp. Atrial Fibrillation Drug Pipeline, H2- 2019
3.10 Dong-A Socio Holdings Co Ltd Atrial Fibrillation Drug Pipeline, H2- 2019
3.11 Espero BioPharma Inc Atrial Fibrillation Drug Pipeline, H2- 2019
3.12 G3 Pharmaceuticals Inc Atrial Fibrillation Drug Pipeline, H2- 2019
3.13 Gilead Sciences Inc Atrial Fibrillation Drug Pipeline, H2- 2019
3.14 HUYA Bioscience International Atrial Fibrillation Drug Pipeline, H2- 2019
3.15 InCarda Therapeutics Inc Atrial Fibrillation Drug Pipeline, H2- 2019
3.16 Merck & Co Inc Atrial Fibrillation Drug Pipeline, H2- 2019
3.17 Milestone Pharmaceuticals Inc Atrial Fibrillation Drug Pipeline, H2- 2019
3.18 Nissan Chemical Industries Ltd Atrial Fibrillation Drug Pipeline, H2- 2019
3.19 OMEICOS Therapeutics GmbH Atrial Fibrillation Drug Pipeline, H2- 2019
3.20 Rhythm Therapeutics Inc Atrial Fibrillation Drug Pipeline, H2- 2019
3.21 The Geneva Biotech Center SA Atrial Fibrillation Drug Pipeline, H2- 2019
3.22 Toa Eiyo Ltd Atrial Fibrillation Drug Pipeline, H2- 2019
3.23 Verseon Corp Atrial Fibrillation Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Atrial Fibrillation- Phase 1 Drug Details
4.2 Atrial Fibrillation- Phase 1 Drug Overview
4.3 Atrial Fibrillation- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Atrial Fibrillation- Phase 2 Drug Details
5.2 Atrial Fibrillation- Phase 2 Drug Overview
5.3 Atrial Fibrillation- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Atrial Fibrillation- Phase 3 Drug Details
6.2 Atrial Fibrillation- Phase 3 Drug Overview
6.3 Atrial Fibrillation- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Atrial Fibrillation- Pre-clinical Phase Drug Details
7.2 Atrial Fibrillation- Pre-clinical Phase Drug Overview
7.3 Atrial Fibrillation- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
